exhibit 
roka bioscience , inc . prices private placement of preferred stock and warrants 
warren , n . j . , sept . {num} {num} / prnewswire / -- roka bioscience , inc . ( roka ) , a molecular diagnostics company focused on providing advanced testing solutions for the detection of foodborne pathogens , today announced that it has entered into a securities purchase agreement in connection with a private placement . upon the closing of the private placement , roka will receive gross proceeds of approximately ${num} million resulting from the sale of approximately {num} shares of the company's series a preferred stock . each share of series a preferred stock is convertible into approximately {num} shares of the company's common stock , which is equivalent to a purchase price of ${num} per common share , or an aggregate of approximately {num} subject to customary adjustments and certain issuance limitations . the purchasers will receive a five-year warrant to purchase approximately {num} shares of the company's common stock , or an aggregate of approximately {num} at an exercise price of ${num} per share for each share of series a preferred stock purchased . 
the closing of the private placement is expected to take place on september {num} {num} and is subject to the satisfaction of customary closing conditions . in connection with the closing , roka will enter into a registration rights agreement with the purchasers of the securities issued in the private placement . roka plans to use the proceeds from the private placement for general corporate purposes . 
following the closing , the company will be required to hold a meeting of its stockholders in order to , among other things , satisfy nasdaq requirements with respect to the issuance of the company's common stock upon conversion of the convertible preferred stock and exercise of the warrants . the conversion of the preferred stock into shares of the company's common stock will occur automatically upon receipt of such stockholder approval . holders of more than {num}% of the company's outstanding shares of common stock have entered into a voting agreement with respect to the meeting of the company's stockholders . 
in addition , the company agreed to use commercially reasonable efforts to file , within {num} days following receipt of the stockholder approval , a registration statement with the securities and exchange commission to register the resale of the shares of common stock underlying the preferred stock and warrants . 
certain funds affiliated with certain members of the company's board of directors , and certain officers and directors of the company , agreed to purchase an aggregate of {num} shares of series a preferred stock , which will be convertible into {num} shares of common stock , and warrants to purchase {num} shares of common stock in the offering . 
this press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities , nor shall there be any sale of these securities in any jurisdiction in which such offer , solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction . 
the securities sold in the private placement have not been registered under the securities act of {num} as amended , or state securities laws and may not be offered or sold in the united states absent registration with the securities and exchange commission or an applicable exemption from such registration requirements . the securities were offered only to accredited investors . pursuant to the terms of the registration rights agreement to be entered into at the closing , roka will agree to file a registration statement with the securities and exchange commission covering the resale of the shares of common stock issuable upon conversion of the series a preferred stock and upon exercise of the warrants . 
terms of the private placement can be found on a form 8-k to be filed with the securities and exchange commission . 
about roka bioscience 
roka bioscience , inc . is a molecular diagnostics company focused on developing and commercializing advanced testing solutions for the food safety testing market . our atlas® detection assays incorporate our advanced 
molecular technologies and are performed on our " sample-in , result out " atlas system that automates all aspects of molecular diagnostic testing on a single , integrated platform . the atlas system and detection assays are designed to provide our customers with accurate and rapid test results with reduced labor costs and improved laboratory efficiencies . for more information , visit http : / / www . rokabio . com . 
forward-looking statements 
this press release contains statements that are forward-looking , including statements regarding roka's expectations regarding the amount and expected uses of the proceeds that will be received in the private placement , the expected closing date of the private placement transaction , and the anticipated filing of a registration statement to cover the resale of the shares sold in the private placement . although roka believes that the forward-looking statements contained herein are reasonable , it can give no assurance that its expectations are correct . forward-looking statements involve risks and uncertainties , many of which are beyond roka's control . these risks , uncertainties and other factors could cause actual results to differ materially from those projected in forward-looking statements . for a detailed description of such risks and uncertainties , you are encouraged to review the official corporate documents filed with the securities and exchange commission on edgar . roka does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof . 
investor or media related inquiries please contact : 
investor contact : 
roka bioscience , inc . 
ir@rokabio . com 
{num}-rokabio ( {num}-{num}-{num} ) 
